Outlook
For fiscal 2022 ending on January 28, 2023, the Company raised its previously issued guidance. The Company now expects net sales in a range of $1.395 billion to $1.410 billion as
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share. This is a 40.91 percent decrease over losses of $(0.44) per share from the same period last year.